This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
India’s pharmaceutical market, currently valued at approximately $60 billion, is projected to double by 2030. The Indian healthcare sector is poised for rapid expansion, driven by a robust pharmaceutical ecosystem. Global pharmaceuticalcompanies have played a pivotal role in transforming the healthcare sector in India.
Yet this amounted to only one quarter of the $5 billion annual goal that was adopted last year at a United Nations High-Level Meeting on TB as part of a plan to end the epidemic by 2030. Just 9% came from the private sector, such as pharmaceuticalcompanies. Meanwhile, the U.S. Continue to STAT+ to read the full story…
Radioligand therapies (RLTs) have received prominent attention from major pharmaceuticalcompanies in treating prostate cancer. billion in sales by 2030, according to GlobalData. billion by 2030, far outshining Xofigo. billion by 2030. bn in sales by 2030 appeared first on Express Pharma.
According to the research, the pharmaceutical quality management systems market is projected to reach $3.97 billion by 2030. Some pharmaceuticalcompanies are increasing their R&D spending to increase product numbers. Also noted in the report was the shift towards cloud-based systems.
billion by 2030, expanding at a compound annual growth rate (CAGR) of 7.2 Pharmaceuticalcompanies globally are significantly investing in R&D. percent between 2022 and 2030 (the forecast period) due to the growing demand for new drugs to tackle the high disease burden worldwide. percent from its 2022 value of $35.1
billion by 2030, displaying a compound annual growth rate (CAGR) of 6.0 The rising requirement for small-scale and encapsulated manufacturing processes necessary to assemble these products make it challenging for many pharmaceuticalcompanies to alter their currently installed capacity.
The Rise of Integrated CDMOs The global biotechnology and pharmaceutical services outsourcing market size was valued at $70.48 from 2023 to 2030. As a result, many companies are turning to integrated CDMOs to simplify their outsourcing processes and improve efficiency.
These developments are influencing pharmaceutical operations by improving research and development (R&D), manufacturing processes, and regulatory compliance. GenAI is being applied to multiple functions in pharmaceuticalcompanies.
In the same statement, Pfizer also announced it has signed a pledge by the US Department of Health and Human Services (HHS) that calls on US healthcare system stakeholders such as hospitals, health systems, payers, suppliers and pharmaceuticalcompanies to reduce GHG emissions and build a more climate resilient healthcare infrastructure.
According to GlobalData’s Pharmaceutical Intelligence Center, Eisai’s Aricept has generated $188 million globally in 2023, and Leqembi is expected to become the dominant drug in neurology, with global sales forecasted to rise from $372 million in 2024 to $7.3 billion in 2030, with a compound annual growth rate (CAGR) of 117.6
Initial data from the CPHI Annual Report 2023, which provides insight from 250 global pharmaceuticalcompanies, reveals that AI (artificial intelligence) is expected to transform every area of the industry, from drug discovery through to drug development , within the next 24-months.
Research by Roots Analysis predicts the pharmaceutical contract manufacturing market will value $140 billion by 2030. percent between 2022-2030. The report noted that there has been “considerable” merger and acquisition activity in recent years within the pharmaceutical contract manufacturing market.
The company hopes to produce this number tenfold by the end of 2030. Radioligand therapy developments in 2023 and 2024 Other companies making progress producing radioligand therapies include Novartis. In January 2024, the pharmaceuticalcompany obtained manufacturing authorisation for its largest radioligand therapy facility.
With other pharmaceuticalcompanies entering the race for developing the first marketed therapy against bronchiectasis, the great opportunity in the market is underlined, says GlobalData , a data and analytics company. According to GlobalData’s Sales and Forecast database, brensocatib’s sales are anticipated to reach $1.2
Positively, it comes at a time when securing fill finish capacity can be a challenge for many pharmaceuticalcompanies. billion by 2030 The post France gets new sterile liquid drug manufacturing facility appeared first on European Pharmaceutical Review. HPAPI contract manufacturing to value $14.6
The profit figure beat forecasts and the UK pharmaceuticalcompany raised its guidance for growth in full-year revenues and earnings from “mid-teens” to “high teens”. It all sounded like another confident step in the march to take global revenues from $46bn in 2023 to $80bn by 2030. Continue reading.
India’s pharmaceutical industry is a global powerhouse. It is already a massive $50 billion market and is projected to grow to $130 billion by 2030. With a similar rationale, large healthcare buyers (like global pharmaceuticalcompanies, retailers, medical chains, etc.)
Recognising the pharmaceutical industry’s substantial contribution to India’s exports, we eagerly anticipate schemes that provide fiscal incentives to encourage such exports. Indian Pharmaceutical sector trying to reach the USD 130 Billion target by 2030.
At the same time, lots of people with experience at multinational pharmaceuticalcompanies have chosen to return home. All these factors will support the growth of in-house R&D-driven pharmaceuticalcompanies and bring more innovative drugs to Asian markets.”. million in 2030.
The global pharmaceutical industry experienced a 17% rise in company filings mentions of blockchain in Q1 2023 compared with the previous quarter, with the highest share accounted for by Bayer, according to GlobalData’s analysis of over 60 pharmaceuticalcompany filings. The overall index for blockchain in Q1 2023 was 74.
This guidance is in line with the WHO’s End TB Strategy, which aims for an 80% fall in worldwide TB incidence and a 90% decrease in TB deaths by 2030, compared with 2015. Sequella is a US-based pharmaceuticalcompany that develops antibiotics to address drug resistant infections.
In this final instalment of IQVIA EMEA Thought Leadership’s Nine for 2023 three-part series, focusing on issues that will change the direction of healthcare and the pharmaceutical industry this year, three key competitive issues for pharmaceuticalcompanies in 2023 are assessed.
The global pharmaceutical industry experienced a 38% drop in company filings mentions of virtual care in Q1 2023 compared with the previous quarter, with the highest share accounted for by ICON with 25% year-on-year decrease, according to GlobalData’s analysis of over 88 pharmaceuticalcompany filings.
According to the World Health Organization, the world will need more than 40 million new doctors, nurses, frontline healthcare workers, and various other healthcare professionals by 2030. This has not escaped the notice of pharmaceuticalcompanies looking to educate patients on topics, with which they may not have the most health literacy.
This would encourage pharmaceuticalcompanies to enhance their R&D efforts, bolstering India’s status as a global leader in innovative healthcare solutions. The government should incentivise research and development (R&D) by increasing the weighted tax deduction for R&D expenditure from 100 per cent to 200 per cent.
“As pipelines shift towards biotechnology, all companies will have to decide between investing in expertise in-house and relying on the pre-existing technological platforms offered by experienced companies.”. The rise of biologics.
billion by 2030. Pharmaceuticalcompanies need to work closely with governments and health authorities to find innovative contracting and payment models, such as outcome-based agreements, which consider the clinical and economic value of the treatment to patients, healthcare systems and society.
According to Grandview Research, the hybrid and decentralized clinical trial (DCT) market will be worth more than 12 billion dollars by 2030. This guide serves as a roadmap for pharmaceuticalcompanies, researchers, healthcare professionals, and anyone interested in understanding the fundamentals of decentralized clinical trials.
. “Novo Nordisk is proud to lead the industry in sustainable business practices, doing our part to give empty pens new purpose,” said the company’s UK general manager, Pinder Sahota. Novo Nordisk is also working towards zero CO2 emissions from operations and transportation by 2030.
From dissecting market trends to envisioning future in near (2030) and long-term (2047), vriddhi 2024 provided a platform for everyone to engage, collaborate, and chart a course towards sustainable growth. Daara Patel, Secretary General of IDMA, with his chivalrous demeanour was earnest to draw participation from all stakeholders.
Specifically, the company formed a consortium with other pharmaceuticalcompanies to secure power purchase agreements for their suppliers. In October 2021, Pfizer itself sealed a 15-year virtual power purchase agreement with Vesper Energy that would see the latter company deliver 310 megawatts of renewable energy.
“As the contribution of costs of organic chemicals used as feedstock to the operating expenditures is small, the pharmaceuticalcompanies can spearhead and guide the transition.” So, when could the goal of a net zero pharmaceutical industry be achieved?
Lastly, there is growing prominence and interest in radioligand therapeutics within major pharmaceuticalcompanies, who are increasingly investing in this field, evident through recent acquisitions of Point Biopharma and RayzeBio. What makes targeted alpha therapies a promising new approach against cancer?
At its Biocon Park campus in Bengaluru the company set up and commissioned a new microbial cGMP facility and expanded its mammalian cell manufacturing facility Meanwhile, Bristol Myers Squibb (BMS), one of the world’s largest pharmaceuticalcompanies, celebrated 25 years of collaboration with Syngene in March 2023.
There has been an amendment under income tax provisions to disallow such expenses incurred by pharmaceuticalcompanies in violation of MCI regulations. – million nurses/midwives in the total stock by 2030. A recent WHO report estimated a shortage of about 1.8 million doctors and 0.65
Brimming with potential As per an Invest India report of 2023, the Indian Bioeconomy, valued at $137 billion in 2023, is targeted to reach $150 billion by 2025 and $300 billion by 2030. IBER Report 2023 divulges, “The biopharma vaccines (non-COVID alone) market makes a significant daily contribution of approximately $38 million.
billion category in 2022 to $54 billion by 2030. Another question is whether pharmaceuticalcompanies will improve their game by getting approval for an oral version of GLP-1.
According to a report by The American Hospital Association , the number of Americans with chronic medical conditions will grow by a projected 9% between 2020 and 2030, an increase of 14 million people. Some disease states are projected to experience even higher increases in patient volume.
According to a report by The American Hospital Association , the number of Americans with chronic medical conditions will grow by a projected 9% between 2020 and 2030, an increase of 14 million people. Some disease states are projected to experience even higher increases in patient volume.
According to a report by The American Hospital Association , the number of Americans with chronic medical conditions will grow by a projected 9% between 2020 and 2030, an increase of 14 million people. Some disease states are projected to experience even higher increases in patient volume.
Another recent change is the timelier release of scientific information; rather than holding on to clinical trial findings until the ‘perfect’ opportunity to present them at a major congress, 2020 increasingly saw pharmaceuticalcompanies make data public in real time. What are the associated challenges? Conclusion.
Eli Lilly has achieved significant gains in the past quarter, leading to it becoming the most valuable pharmaceuticalcompany in the world, with a market cap of $420bn, surpassing Johnson & Johnson. There have been several Phase III trials for Mounjaro, with SURMOUNT-1 demonstrating a weight loss of up to 22.5%
Jamie Phares, managing director, The Janssen PharmaceuticalCompanies of Johnson & Johnson in the Gulf Cooperation Council (GCC), talks about how the healthcare industry needs to come together to reduce its environmental impact and further protect public health. About the author.
billion by 2030 (2). Similarly, India’s pharmaceutical contract manufacturing market is expected to increase at a CAGR of 14.67 Manufacturing costs in India are also 30 – 35 per cent lower than those in the US and Europe (5), further sweetening the deal for global pharmaceuticalcompanies. per cent, hitting $44.63
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content